Nanalysis Scientific Corp. (NSCIF)
| Market Cap | 14.24M -31.1% |
| Revenue (ttm) | 29.27M -11.8% |
| Net Income | -4.13M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 16.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,500 |
| Average Volume | 69,263 |
| Open | 0.0800 |
| Previous Close | 0.1018 |
| Day's Range | 0.0800 - 0.0931 |
| 52-Week Range | 0.0800 - 0.2120 |
| Beta | 0.12 |
| RSI | 49.42 |
| Earnings Date | Apr 8, 2026 |
About Nanalysis Scientific
Nanalysis Scientific Corp. develops, manufactures, and sells magnetic resonance technology products in Canada, the United States, Europe, Asia, and internationally. The company operates through Scientific Equipment and Security Services segment. It offers nuclear magnetic resonance (NMR) spectrometers; magnetic resonance test, and measurement and diagnostic system; 60-NMR platform; 100-NMR platform; 60-TEACH Platform; QUAD NMR Console; and Cameleon 4 console, a compact alternative to facilitate MRI for teaching. The company also provides softwa... [Read more]
Financial Performance
In 2025, Nanalysis Scientific's revenue was 40.13 million, a decrease of -11.79% compared to the previous year's 45.50 million. Losses were -5.66 million, -58.44% less than in 2024.
Financial numbers in CAD Financial StatementsNews
Nanalysis Scientific Corp (NSCIF) Q4 2025 Earnings Call Highlights: Navigating Challenges and ...
Nanalysis Scientific Corp (NSCIF) Q4 2025 Earnings Call Highlights: Navigating Challenges and Focusing on Proprietary Growth
Q4 2025 Nanalysis Scientific Corp Earnings Call Transcript
Q4 2025 Nanalysis Scientific Corp Earnings Call Transcript
Nanalysis Scientific Earnings Call Transcript: Q4 2025
Q4 2025 revenue declined 13% year-over-year to CAD 10.7 million, mainly due to lower Scientific Equipment sales and the exit from third-party resale businesses. Gross margins and adjusted EBITDA also decreased, but operational improvements, new funding, and a focus on proprietary products position the company for improved profitability.
Nanalysis Announces Fourth Quarter and Full Year 2025 Results
Reports Quarterly Revenue of $10.7 Million and Adjusted EBITDA of $1.2 Million Full Year Revenue of $40.1 Million and Adjusted EBITDA of $903 Thousand CALGARY, AB, April 8, 2026 /PRNewswire/ - Nanalys...
Nanalysis Announces Fourth Quarter and Full Year 2025 Results
Reports Quarterly Revenue of $10.7 Million and Adjusted EBITDA of $1.2 Million Full Year Revenue of $40.1 Million and Adjusted EBITDA of $903 Thousand CALGARY, AB , April 8, 2026 /CNW/ - Nanalysis Sci...
Nanalysis Announces Fourth Quarter and Full Year 2025 Conference Call
Hosting Call at 10am ET on Thursday, April 9th CALGARY, AB, April 2, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR instruments and imag...
Nanalysis Announces Grant of Options and Restricted Share Units
CALGARY, AB, March 4, 2026 /PRNewswire/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI) (FRA: 1N1) announces the Company's Board of Directors has granted 1,210,000 restricted...
Nanalysis Announces Closing of Second Tranche to Complete its $3.4 Million Offering
CALGARY, AB, Jan. 26, 2026 /PRNewswire/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") ( TSXV: NSCI , OTCQX: NSCIF , FRA: 1N1) is pleased to announce, further to its December 8, 2025 and...
Nanalysis Announces Upsize to Private Placement and Closing of the First Tranche
CALGARY, AB , Dec. 23, 2025 /PRNewswire/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") ( TSXV: NSCI , OTCQX: NSCIF , FRA: 1N1) is pleased to announce that it has closed the first tranch...
Nanalysis Announces $2.5 Million Private Placement
CALGARY, AB , Dec. 8, 2025 /PRNewswire/ -Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) is pleased to announce that it intends to complete a non-brokere...
Nanalysis Announces Third Quarter 2025 Results
CALGARY, AB , Nov. 24, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and ...
Nanalysis Scientific Earnings Call Transcript: Q3 2025
Q3 2025 revenue declined 12% year-over-year due to discontinued business lines and global demand softness, while security services revenue grew 10%. Gross margins fell in product sales but improved in security services, and supply chain issues were resolved.
Nanalysis Announces Third Quarter 2025 Conference Call
Hosting Call at 4:15 pm ET on Monday, November 24th CALGARY, AB , Nov. 18, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable N...
Nanalysis Announces Change of Management
Not for distribution to U.S. newswire services or dissemination in the United States CALGARY, AB , Nov. 14, 2025 /PRNewswire/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI) (...
Nanalysis announces support from Wiley for NMR Instruments in KnowItAll 2026
CALGARY, AB , Oct. 7, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable Nuclear Magnetic Resonance (NMR) instruments and Magne...
Nanalysis Chosen by IMRIS as Critical Component MRI Supplier
CALGARY, AB , Sept. 3, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable Nuclear Magnetic Resonance (NMR) instruments and Magn...
Nanalysis Scientific Earnings Call Transcript: Q2 2025
Second quarter results were disappointing due to economic uncertainty and delayed customer orders, but sequential gross margin improvements were achieved, especially in services. Confidence remains high for a strong second half as supply chain risks are addressed.
Nanalysis Announces Second Quarter 2025 Results
CALGARY, AB , Aug. 28, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial a...
Nanalysis Scientific Earnings Call Transcript: Q2 2025
Q2 2025 revenue fell 16.5% year-over-year due to lower product sales, but gross margins improved to 61%. Security Services revenue grew 9.9%, and management expects margin gains and delayed sales to materialize in the second half of 2025.
Nanalysis Announces Second Quarter 2025 Conference Call
Hosting Call at 5:00 pm ET on Thursday, August 28th European Q&A Session on Friday, August 29th at 8:30am ET CALGARY, AB , Aug. 21, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV:...
Nanalysis Announces First Regulated Assay for Pharmaceutical Quality Control via Benchtop NMR Accepted by the United States Pharmacopeia (USP) and European Pharmacopeia (Ph. Euro)
CALGARY, AB , July 9, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and MRI technology for industrial and res...
Nanalysis Scientific Earnings Call Transcript: Q1 2025
Q1 2025 saw revenue decline 5% year-over-year but gross margin and adjusted EBITDA improved, with net loss narrowing by CAD 1.2 million. Management remains confident in the 2025 outlook, citing strong sales funnel and positive operating cash flow.
Nanalysis Announces First Quarter 2025 Results
Delivers Another Quarter of Positive Adjusted EBITDA & Operating Cash Flow CALGARY, AB , May 28, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), ...
Nanalysis Announces First Quarter 2025 Conference Call
Hosting Call at 5:00 pm ET on Wednesday, May 28th European Q&A Session on Thursday, May 29th at 8:30am ET CALGARY, AB , May 15, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NS...
Nanalysis Scientific Earnings Call Transcript: Q4 2024
Positive gross margins and operational efficiency were achieved, with normalized Q4 net loss at CAD 400,000 and strong cash flow. A CAD 7 million impairment was recorded, but future growth and margin expansion remain priorities.